Stuart Silverman

Summary

Affiliation: Cedars-Sinai Medical Center
Country: USA

Publications

  1. pmc The Direct Assessment of Nonvertebral Fractures in Community Experience (DANCE) study: 2-year nonvertebral fragility fracture results
    S Silverman
    Cedars Sinai UCLA Medical Center and OMC Clinical Research Center, 8641 Wilshire Blvd, Suite 301, Beverly Hills, CA 90211, USA
    Osteoporos Int 24:2309-17. 2013
  2. doi request reprint Patient weighting of osteoporosis medication attributes across racial and ethnic groups: a study of osteoporosis medication preferences using conjoint analysis
    S Silverman
    Cedars Sinai Medical Center, Los Angeles, CA, USA
    Osteoporos Int 24:2067-77. 2013
  3. doi request reprint Impact of clinical fractures on health-related quality of life is dependent on time of assessment since fracture: results from the FREEDOM trial
    S Silverman
    Cedars Sinai UCLA and OMC Clinical Research Center, 8641 Wilshire Boulevard, Suite 301, Beverly Hills, CA 90211, USA
    Osteoporos Int 23:1361-9. 2012
  4. doi request reprint Impact of bone turnover markers and/or educational information on persistence to oral bisphosphonate therapy: a community setting-based trial
    S L Silverman
    UCLA Cedars Sinai, Los Angeles, USA
    Osteoporos Int 23:1069-74. 2012
  5. pmc Anabolic therapies
    Nancy E Lane
    Aging Center, Medicine and Rheumatology, University of California at Davis Medical Center, 4800 2nd Avenue, Suite 2600, Sacramento, CA 95817, USA
    Curr Osteoporos Rep 8:23-7. 2010
  6. ncbi request reprint New therapies for osteoporosis: zoledronic acid, bazedoxifene, and denosumab
    Stuart L Silverman
    Curr Osteoporos Rep 7:91-5. 2009
  7. ncbi request reprint Glucocorticoid-induced osteoporosis
    Stuart L Silverman
    Cedars Sinai UCLA and OMC Clinical Research Center, 8641 Wilshire Boulevard, Beverly Hills, CA 90211, USA
    Curr Osteoporos Rep 7:23-6. 2009
  8. ncbi request reprint Compliance and persistence with osteoporosis therapies
    Stuart L Silverman
    University of California, Los Angeles Cedars Sinai, 8641 Wilshire Boulevard, Suite 301, Beverly Hills, CA 90211, USA
    Curr Rheumatol Rep 10:118-22. 2008
  9. doi request reprint From randomized controlled trials to observational studies
    Stuart L Silverman
    Cedars Sinai Medical Center, David Geffen School of Medicine UCLA, OMC Clinical Research Center, Beverly Hills, Calif 90211, USA
    Am J Med 122:114-20. 2009
  10. ncbi request reprint Selecting patients for osteoporosis therapy
    Stuart L Silverman
    Cedars Sinai Medical Center and University of California, Los Angeles, 8641 Wilshire Blvd, Suite 301, Beverly Hills, CA 90211, USA
    Ann N Y Acad Sci 1117:264-72. 2007

Detail Information

Publications51

  1. pmc The Direct Assessment of Nonvertebral Fractures in Community Experience (DANCE) study: 2-year nonvertebral fragility fracture results
    S Silverman
    Cedars Sinai UCLA Medical Center and OMC Clinical Research Center, 8641 Wilshire Blvd, Suite 301, Beverly Hills, CA 90211, USA
    Osteoporos Int 24:2309-17. 2013
    ..The incidence of new NVFX decreased for patients receiving TPTD treatment for greater than 6 months. No new significant safety findings were observed in this large trial...
  2. doi request reprint Patient weighting of osteoporosis medication attributes across racial and ethnic groups: a study of osteoporosis medication preferences using conjoint analysis
    S Silverman
    Cedars Sinai Medical Center, Los Angeles, CA, USA
    Osteoporos Int 24:2067-77. 2013
    ..Our study showed that postmenopausal women differ in the ranking of OP medication attributes based on age, educational level, income, and prior fracture history...
  3. doi request reprint Impact of clinical fractures on health-related quality of life is dependent on time of assessment since fracture: results from the FREEDOM trial
    S Silverman
    Cedars Sinai UCLA and OMC Clinical Research Center, 8641 Wilshire Boulevard, Suite 301, Beverly Hills, CA 90211, USA
    Osteoporos Int 23:1361-9. 2012
    ..The largest declines were observed when the assessment was <3 months post fracture. The largest impact of incident clinical fractures was on physical function, and that of incident clinical vertebral fractures was on back pain...
  4. doi request reprint Impact of bone turnover markers and/or educational information on persistence to oral bisphosphonate therapy: a community setting-based trial
    S L Silverman
    UCLA Cedars Sinai, Los Angeles, USA
    Osteoporos Int 23:1069-74. 2012
    ..We found that reporting bone turnover results and/or educational information did not affect persistence...
  5. pmc Anabolic therapies
    Nancy E Lane
    Aging Center, Medicine and Rheumatology, University of California at Davis Medical Center, 4800 2nd Avenue, Suite 2600, Sacramento, CA 95817, USA
    Curr Osteoporos Rep 8:23-7. 2010
    ....
  6. ncbi request reprint New therapies for osteoporosis: zoledronic acid, bazedoxifene, and denosumab
    Stuart L Silverman
    Curr Osteoporos Rep 7:91-5. 2009
    ..Bazedoxifene, an estrogen agonist/antagonist, has significantly reduced the risk of vertebral fracture in postmenopausal women; a post hoc analysis showed reduction in risk of nonvertebral fracture in high-risk women...
  7. ncbi request reprint Glucocorticoid-induced osteoporosis
    Stuart L Silverman
    Cedars Sinai UCLA and OMC Clinical Research Center, 8641 Wilshire Boulevard, Beverly Hills, CA 90211, USA
    Curr Osteoporos Rep 7:23-6. 2009
    ..This article reviews current information on the epidemiology, pathophysiology, and clinical studies that support using bone-active agents to prevent and treat GIO...
  8. ncbi request reprint Compliance and persistence with osteoporosis therapies
    Stuart L Silverman
    University of California, Los Angeles Cedars Sinai, 8641 Wilshire Boulevard, Suite 301, Beverly Hills, CA 90211, USA
    Curr Rheumatol Rep 10:118-22. 2008
    ..Patients on weekly therapies are more compliant and persistent than those on daily dosing. Data have also shown decreased fracture risk, decreased health care utilization, and lower costs in compliant and persistent patients...
  9. doi request reprint From randomized controlled trials to observational studies
    Stuart L Silverman
    Cedars Sinai Medical Center, David Geffen School of Medicine UCLA, OMC Clinical Research Center, Beverly Hills, Calif 90211, USA
    Am J Med 122:114-20. 2009
    ..Furthermore, well-designed observational studies can identify clinically important differences among therapeutic options and provide data on long-term drug effectiveness and safety...
  10. ncbi request reprint Selecting patients for osteoporosis therapy
    Stuart L Silverman
    Cedars Sinai Medical Center and University of California, Los Angeles, 8641 Wilshire Blvd, Suite 301, Beverly Hills, CA 90211, USA
    Ann N Y Acad Sci 1117:264-72. 2007
    ..Intervention thresholds based on absolute risk will be defined regionally based on each nation's ability and willingness to pay...
  11. pmc Oral bisphosphonate compliance and persistence: a matter of choice?
    S L Silverman
    Cedars Sinai UCLA OMC, 8641 Wilshire Blvd, Suite 301, Beverly Hills, CA 90211, USA
    Osteoporos Int 22:21-6. 2011
    ..We need to understand better reasons for poor compliance before effective interventions can be developed. Forgetfulness is only a small part of poor compliance. Patient preferences must be considered in medication decision making...
  12. pmc Compliance and persistence with osteoporosis medications: a critical review of the literature
    Stuart Silverman
    Cedars Sinai UCLA, 8641 Wilshire Blvd, Suite 301, Beverly Hills, CA 90211, USA
    Rev Endocr Metab Disord 11:275-80. 2010
    ..It also looks at compliance and persistence across multiple medical conditions, examining the importance of prescription fulfillment, intentional choice, causation and possible interventions...
  13. doi request reprint Identifying fibromyalgia-associated symptoms and conditions from a clinical perspective: a step toward evaluating healthcare resource utilization in fibromyalgia
    Stuart L Silverman
    Department of Medicine, Cedars Sinai UCLA, Los Angeles, California 90211, USA
    Pain Pract 10:520-9. 2010
    ....
  14. pmc New selective estrogen receptor modulators (SERMs) in development
    Stuart L Silverman
    Cedars Sinai UCLA, 8641 Wilshire Boulevard, Suite 301, Beverly Hills, CA 90211, USA
    Curr Osteoporos Rep 8:151-3. 2010
    ..I will discuss their effect on bone, breast, and the cardiovascular system, as well as on safety...
  15. pmc Osteoporosis therapies: evidence from health-care databases and observational population studies
    Stuart L Silverman
    Cedars Sinai Medical Center, Department of Medicine and Rheumatology, David Geffen School of Medicine at UCLA, OMC Clinical Research Center, 8641 Wilshire Blvd Suite 301, Beverly Hills, CA 90211, USA
    Calcif Tissue Int 87:375-84. 2010
    ....
  16. pmc The utility and limitations of FRAX: A US perspective
    Stuart L Silverman
    Curr Osteoporos Rep 8:192-7. 2010
    ..Finally, the values obtained from FRAX should not take the place of good clinical judgment...
  17. doi request reprint Bisphosphonate use in conditions other than osteoporosis
    Stuart L Silverman
    Cedars Sinai University of California at Los Angeles, Beverly Hills, California, USA
    Ann N Y Acad Sci 1218:33-7. 2011
    ..Bisphophonates may have potential use in periprosthetic bone loss, osteonecrosis of the hip, fibrous dysplasia, and calcinosis in juvenile dermatomyositis...
  18. doi request reprint Teriparitide update
    Stuart L Silverman
    Cedars Sinai Bone Center of Excellence, 8641 Wilshire Boulevard, Suite 301, Beverly Hills, CA 90211, USA
    Rheum Dis Clin North Am 37:471-7, vii. 2011
    ..Many questions about the use of TPD remain including use of follow-up therapy, combination therapy, sequential therapy, and its potential role in fracture healing and treatment of back pain related to osteoporosis...
  19. ncbi request reprint Recommendations for the clinical evaluation of agents for treatment of osteoporosis: consensus of an expert panel representing the American Society for Bone and Mineral Research (ASBMR), the International Society for Clinical Densitometry (ISCD), and the
    Stuart L Silverman
    Division of Rheumatology, Cedars Sinai Medical Center and the David Geffen School of Medicine, University of California, Los Angeles, California, USA
    J Bone Miner Res 23:159-65. 2008
    ....
  20. ncbi request reprint Recent developments in bisphosphonate therapy
    Stuart L Silverman
    UCLA Cedars Sinai, Osteoporosis Medical Center, Beverly Hills, California 90211, USA
    Semin Arthritis Rheum 37:1-12. 2007
    ..To provide a review of current developments in bisphosphonates indicated for the treatment of several rheumatologic conditions, including postmenopausal and glucocorticoid-induced osteoporosis...
  21. ncbi request reprint Calcitonin
    S L Silverman
    Department of Medicine, University of California Los Angeles, USA
    Rheum Dis Clin North Am 27:187-96. 2001
    ..Calcitonin produces small increments in the bone mass of the spine and modestly reduces bone turnover in women with osteoporosis. No significant effect on nonvertebral fractures has been observed. Calcitonin may have analgesic benefit...
  22. ncbi request reprint Quality-of-life issues in osteoporosis
    Stuart L Silverman
    Division of Rheumatology, Cedars Sinai Medical Center, 8641 Wilshire Blvd, Suite 301, Beverly Hills, CA 90211, USA
    Curr Rheumatol Rep 7:39-45. 2005
    ....
  23. pmc Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study
    S L Silverman
    Cedars Sinai Medical Center and David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA 90211, USA
    Osteoporos Int 18:25-34. 2007
    ..The aim of this observational study was to observe, in clinical practice, the incidence of hip and nonvertebral fractures among women in the year following initiation of once-a-week dosing of either risedronate or alendronate...
  24. ncbi request reprint Comparison of fracture, cardiovascular event, and breast cancer rates at 3 years in postmenopausal women with osteoporosis
    Stuart L Silverman
    Division of Rheumatology, Cedars Sinai Medical Center, Los Angeles, California, USA
    J Am Geriatr Soc 52:1543-8. 2004
    ..To compare event rates for osteoporotic fractures, cardiovascular events, and breast cancer in postmenopausal women with osteoporosis...
  25. pmc Effect of acetaminophen and fluvastatin on post-dose symptoms following infusion of zoledronic acid
    S L Silverman
    Cedars Sinai Medical Center and David Geffen School of Medicine, University of California, Los Angeles, CA 90211, USA
    Osteoporos Int 22:2337-45. 2011
    ..Acetaminophen, but not fluvastatin, significantly reduced the incidence and severity of post-dose symptoms...
  26. ncbi request reprint Calcitonin
    Stuart L Silverman
    Department of Medicine and Rheumatology, Cedars Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
    Endocrinol Metab Clin North Am 32:273-84. 2003
    ..Calcitonin may also be indicated for women who are unable to take bisphosphonates because of impaired renal function...
  27. ncbi request reprint Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and/or prevalent vertebral fracture: results from the Multiple Outcomes of Raloxifene Evaluation (MORE) study
    Stuart L Silverman
    Cedars Sinai Medical Center, UCLA, Greater Los Angeles Veterans Administration Health System, Los Angeles, California, USA
    J Rheumatol 34:140-4. 2007
    ..To examine the prevalence of depressive symptoms in a cross-sectional study of postmenopausal women with osteoporosis with and without prevalent vertebral fracture...
  28. ncbi request reprint Adherence to medications for the treatment of osteoporosis
    Stuart Silverman
    Department of Medicine, Division of Rheumatology, Cedars Sinai Medical Center UCLA, The Osteoporosis Medical Center, 8641 Wilshire Boulevard, Suite 301, Beverly Hills, CA 90211, USA
    Rheum Dis Clin North Am 32:721-31. 2006
    ..There is a lack of understanding about why patients are not staying on therapy. Potential solutions include newer medications with extended dosing intervals, monitoring, and an open physician-patient relationship...
  29. ncbi request reprint The analgesic role of calcitonin following osteoporotic fracture
    S L Silverman
    Cedars Sinai Medical Center, GLA VA Health System, OMC Clinical Research Center, University of California, Los Angeles, USA
    Osteoporos Int 13:858-67. 2002
    ..The mechanism(s) by which SCT induces pain relief has (have) not been conclusively shown. Neither a direct receptor-mediated action nor an indirect endorphin-mediated effect can be ruled out...
  30. ncbi request reprint The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis: results from the Multiple Outcomes of Raloxifene Evaluation Study
    S L Silverman
    Cedars Sinai Medical Center, Greater Los Angeles VA Health System, University of California, USA
    Arthritis Rheum 44:2611-9. 2001
    ....
  31. ncbi request reprint Selecting patients for osteoporosis therapy
    Stuart L Silverman
    University of California, Los Angeles, 8641 Wilshire Blvd, Suite 301, Beverly Hills, CA 90211, USA
    Curr Osteoporos Rep 4:91-5. 2006
    ..These risk factors can be integrated to predict a 10-year absolute risk or probability of fracture. Intervention thresholds based on absolute risk will be defined regionally based on each nation's ability and willingness to pay...
  32. pmc Toward characterization and definition of fibromyalgia severity
    Stuart Silverman
    Cedars Sinai Medical Center, Los Angeles, CA, USA
    BMC Musculoskelet Disord 11:66. 2010
    ..The objective of this study was to evaluate whether patient self-reported severity of FM is associated with severity of pain and sleep interference and the presence of core co-morbidities...
  33. ncbi request reprint Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases
    Ethel S Siris
    Toni Stabile Osteoporosis Center, Department of Medicine, Columbia University Medical Center, Harkness Pavilion 9 964, 180 Fort Washington Ave, New York, NY 10032, USA
    Mayo Clin Proc 81:1013-22. 2006
    ..To characterize the relationships between adherence (complance and persistence) to bisphosphonate therapy and risk of specific fracture types in postmenopausal women...
  34. doi request reprint Psychometric properties of the Osteoporosis-specific Morisky Medication Adherence Scale in postmenopausal women with osteoporosis newly treated with bisphosphonates
    Kristi Reynolds
    Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA
    Ann Pharmacother 46:659-70. 2012
    ..An evaluation of the measurement properties of the Osteoporosis-Specific Morisky Medication Adherence Scale (OS-MMAS) was needed...
  35. ncbi request reprint The economic burden of fibromyalgia: comparative analysis with rheumatoid arthritis
    Stuart Silverman
    University of California, Los Angeles, CA, USA
    Curr Med Res Opin 25:829-40. 2009
    ..Patients with both illnesses were isolated and reported as a third group. A secondary analysis of work loss was performed for an employed subset of these patients...
  36. doi request reprint Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: the eValuation of IBandronate Efficacy (VIBE) database fracture study
    S T Harris
    University of California, San Francisco, CA 94115 3044, USA
    Bone 44:758-65. 2009
    ..Ibandronate patients had a significantly lower relative risk of vertebral fracture than weekly BP patients; the clinical implications of these findings require further exploration and validation...
  37. ncbi request reprint The role of socioeconomic status on hip fracture
    D S Zingmond
    Division of General Internal Medicine and Health Services Research, Department of Medicine, The David Geffen School of Medicine at UCLA, 911 Broxton Plaza, Los Angeles, CA, 90095 1736, USA
    Osteoporos Int 17:1562-8. 2006
    ..Race/ethnicity is a major determinant of hip fracture risk. Although socioeconomic status (e.g., income and acculturation) is often associated with race/ethnicity, its impact on hip fracture incidence is less well understood...
  38. ncbi request reprint Increasing hip fracture incidence in California Hispanics, 1983 to 2000
    David S Zingmond
    Division of General Internal Medicine, The David Geffen School of Medicine at UCLA, 911 Broxton Plaza, Los Angeles, CA 90095 1736, USA
    Osteoporos Int 15:603-10. 2004
    ..Hip fracture incidence in non-Hispanic whites (NHW) has decreased nationwide for the past 20 years. Little is known regarding hip fracture incidence among Hispanics, the largest, fastest growing minority in the United States...
  39. ncbi request reprint The impact of incident vertebral and non-vertebral fragility fractures on health-related quality of life in established postmenopausal osteoporosis: results from the teriparatide randomized, placebo-controlled trial in postmenopausal women
    Alan K Oglesby
    Eli Lilly and Company, Global Economic Affairs, Indianapolis, Indiana 46285, USA
    J Rheumatol 30:1579-83. 2003
    ..7) with osteoporosis who participated in a clinical trial to examine the anti-fracture efficacy of teriparatide [rhPTH(1-34)] injection...
  40. ncbi request reprint Redefining osteoporosis treatment: Who to treat and how long to treat
    E Michael Lewiecki
    New Mexico Clinical Research and Osteoporosis Center, Albuquerque, New Mexico 87106, USA
    Arq Bras Endocrinol Metabol 50:694-704. 2006
    ..Patients at high risk for fracture should be considered for pharmacological therapy, which can reduce fracture risk by about 50%...
  41. ncbi request reprint Methodological considerations in using claims databases to evaluate persistence with bisphosphonates for osteoporosis
    Joyce A Cramer
    Department of Psychiatry, Yale UniversitySchool of Medicine, 950 Campbell Avenue 151D, West Haven, CT 06516 2770, USA
    Curr Med Res Opin 23:2369-77. 2007
    ..Bisphosphonates (BPs) are used as an example because of the availability of diverse dosing options that can create a unique set of challenges for persistence analyses...
  42. ncbi request reprint Osteonecrosis of the jaws and bisphosphonates
    David G Pendrys
    Department of Oral Health and Diagnostic Sciences, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030, USA
    Curr Osteoporos Rep 6:31-8. 2008
    ..Thus, the benefits of bisphosphonate therapy appear to outweigh the risks. Recommendations have been established for the oral health management of patients with a history of bisphosphonate therapy...
  43. ncbi request reprint Do estrogen or selective estrogen receptor modulators improve quality of life for women with postmenopausal osteoporosis?
    Deborah T Gold
    Department of Psychiatry, Center for the Study of Aging and Human Development, Box 3003, Duke University Medical Center, Durham, NC 27710, USA
    Curr Osteoporos Rep 5:3-7. 2007
    ..Raloxifene decreases risk of invasive breast cancer and may be considered in women at high risk of breast cancer. Decision making about osteoporosis treatment should also consider the impact of the treatment on HRQOL...
  44. ncbi request reprint Rationale, objectives and design of the Direct Analysis of Nonvertebral Fracture in the Community Experience (DANCE) study
    Paul D Miller
    Department of Medicine, University of Colorado Health Sciences Center and Colorado Center for Bone Research, Denver, CO, USA
    Osteoporos Int 17:85-90. 2006
    ..DANCE will provide data on the effectiveness and tolerability of teriparatide therapy in clinical practice that will complement the results of published controlled clinical trials...
  45. doi request reprint Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment
    Sundeep Khosla
    J Oral Maxillofac Surg 66:1320-1; author reply 1321-2. 2008
  46. ncbi request reprint Relationship of health related quality of life to prevalent and new or worsening back pain in postmenopausal women with osteoporosis
    Stuart L Silverman
    Cedars Sinai Medical Center, GLA VA Health System, OMC Clinical Research Center, Department of Medicine, University of California Los Angeles, California, USA
    J Rheumatol 32:2405-9. 2005
    ..To examine the association between back pain and health related quality of life (HRQOL) in postmenopausal women with osteoporosis...
  47. ncbi request reprint An evaluation of patient preferences for osteoporosis medication attributes: results from the PREFER-US study
    Thomas W Weiss
    Merck and Co, Inc, West Point, PA 19486, USA
    Curr Med Res Opin 22:949-60. 2006
    ..To evaluate preferences for eight medication attributes that women may consider when evaluating prescription osteoporosis medications...
  48. ncbi request reprint Osteoporosis self-management: Choices For Better Bone Health
    Deborah T Gold
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27710, USA
    South Med J 97:551-4. 2004
    ..Choices is a group education course directed to postmenopausal women who are at risk or already affected by osteoporosis, and has shown positive results in early evaluations...
  49. ncbi request reprint Reduced fracture rates observed only in patients with proper persistence and compliance with bisphosphonate therapies
    Stuart L Silverman
    Department of Medicine and Rheumatology, Cedars Sinai Medical Center UCLA, Beverly Hills, California 90211, USA
    South Med J 100:1214-8. 2007
    ..Measures to improve persistence and compliance with osteoporosis medications are needed if patients are to achieve the full clinical benefit of treatment...
  50. ncbi request reprint Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research
    Sundeep Khosla
    J Bone Miner Res 22:1479-91. 2007
    ..This report summarizes the findings and recommendations of the task force...
  51. ncbi request reprint Methodology questioned
    Stuart L Silverman
    J Am Dent Assoc 139:537-8; author reply 538. 2008